TITLE

Denosumab Injection (Prolia)

AUTHOR(S)
Elliot, William T.; Chan, James
PUB. DATE
August 2010
SOURCE
Internal Medicine Alert;8/15/2010, Vol. 32 Issue 15, p117
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the approval of the first receptor activator of nuclear factor kappa-B ligand (RANKL) for the treatment of osteoporosis.
ACCESSION #
53751409

 

Related Articles

  • The Time Course Changes in Bone Metabolic Markers after Administering the Anti-Receptor Activator of Nuclear Factor-Kappa B Ligand Antibody and Drug Compliance among Patients with Osteoporosis.  // Asian Spine Journal;2015, Vol. 9 Issue 6, p999 

    A correction to the article "The Time Course Changes in Bone Metabolic Markers After Administering the Anti-Receptor Activator of Nuclear Factor-Kappa B Ligand Antibody and Drug Compliance Among Patients With Osteoporosis" that was published in the previous issue is presented.

  • Spotlight on Denosumab in Postmenopausal Osteoporosist. Moen, Marit D.; Keam, Susan J. // BioDrugs;2011, Vol. 25 Issue 4, p261 

    Denosumab (Prolia) is a human recombinant monoclonal antibody that is approved for the treatment of postmenopausal osteoporosis in women at high or increased risk of fracture in the US, the EU, and several other countries. Denosumab has a novel mechanism of action; it binds to receptor activator...

  • The Long and the Short of Bone Therapy. Whyte, Michael P. // New England Journal of Medicine;2/23/2006, Vol. 354 Issue 8, p860 

    An editorial is presented that considers the uses of denosumab as a therapy for osteoporosis. Denosumab simulates the actions of osteoprotegerin, which stops the effects of nuclear factor ?B ligand (RANKL). This decreases biochemical markers of bone reabsorption. Denosumab has been shown to...

  • Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Kiechl, Stefan; Wittmann, Jürgen; Giaccari, Andrea; Knoflach, Michael; Willeit, Peter; Bozec, Aline; Moschen, Alexander R; Muscogiuri, Giovanna; Sorice, Gian Pio; Kireva, Trayana; Summerer, Monika; Wirtz, Stefan; Luther, Julia; Mielenz, Dirk; Billmeier, Ulrike; Egger, Georg; Mayr, Agnes; Oberhollenzer, Friedrich; Kronenberg, Florian; Orthofer, Michael // Nature Medicine;Mar2013, Vol. 19 Issue 3, p358 

    Hepatic insulin resistance is a driving force in the pathogenesis of type 2 diabetes mellitus (T2DM) and is tightly coupled with excessive storage of fat and the ensuing inflammation within the liver. There is compelling evidence that activation of the transcription factor nuclear factor-κB...

  • Reduced osteoclastogenesis and RANKL expression in marrow from women taking alendronate. Eslami, Behnam; Zhou, Shuanhu; Eekeren, Inge; LeBoff, Meryl; Glowacki, Julie; Van Eekeren, Inge; LeBoff, Meryl S // Calcified Tissue International;Apr2011, Vol. 88 Issue 4, p272 

    Alendronate (AL) is commonly used for the prevention and treatment of osteoporotic fractures. Little is known about the effects of AL administration on osteoclast differentiation from human marrow progenitor cells. We used marrow discarded during orthopedic surgery to test the hypothesis that...

  • The Anti-inflammatory Effect of Z-Ligustilide in Experimental Ovariectomized Osteopenic Rats. Ma, Zhaoji; Bai, Lunhao // Inflammation;Dec2012, Vol. 35 Issue 6, p1793 

    The purpose of the present study was to investigate the anti-inflammatory activity of Z-Ligustilide (LIG) in experimental ovariectomized (OVX) osteopenic rats. The anti-inflammatory potential of LIG in the regulation of nuclear factor kappa B (NF-κB), maleic dialdehyde (MDA),...

  • Population Pharmacokinetic Meta-Analysis of Denosumab in Healthy Subjects and Postmenopausal Women with Osteopenia or Osteoporosis. Sutjandra, Liviawati; Rodriguez, Rachelle D.; Doshi, Sameer; Ma, Mark; Peterson, Mark C.; Jang, Graham R.; Chow, Andrew T.; Pérez-Ruixo, Juan José // Clinical Pharmacokinetics;2011, Vol. 50 Issue 12, p793 

    Background and Objective: Inhibition of the receptor activator of nuclear factor κ-B ligand (RANKL) is a therapeutic target for treatment of bone disorders associated with increased bone resorption, such as osteoporosis. The objective of this analysis was to characterize the population...

  • POTENTIAL ROLE OF BONE MARROW DERIVED MESENCHYMAL STEM CELLS WITH OR WITHOUT INJECTABLE CALCIUM PHOSPHATE COMPOSITE IN MANAGEMENT OF OSTEOPOROSIS IN RAT MODEL. AHMED, HANAA H.; EL-SAYED MAHDY, EL-SAYED M.; SHOUSHA, WAFAA GH.; RASHED, LAILA A.; ABDO, SARA M. // International Journal of Pharmacy & Pharmaceutical Sciences;2013 Supplement, Vol. 5 Issue Supp 3, p494 

    Objective: The purpose of the present study was to evaluate the possible therapeutic role of bone marrow mesenchymal stem cells (BM-MSCs) alone or in combination with injectable calcium phosphate composite in management of osteoporosis in ovariectomized rats. Methods: The MSCs were harvested...

  • Agelasine D Suppresses RANKL-Induced Osteoclastogenesis via Down-Regulation of c-Fos, NFATc1 and NF - κB. Moo Rim Kang; Sun Ah Jo; Yeo Dae Yoon; Ki Hwan Park; Soo Jin Oh; Jieun Yun; Chang Woo Lee; Ki-Hoan Nam; Youngsoo Kim; Sang-Bae Han; Jiyeon Yu; Jaerang Rho; Jong Soon Kang // Marine Drugs;2014, Vol. 12 Issue 11, p5643 

    In the present study, we investigated the effect of agelasine D (AD) on osteoclastogenesis. Treatment of bone marrow macrophages (BMMs) with receptor activator of nuclear factor KB ligand (RANKL) resulted in a differentiation of BMMs into osteoclasts as evidenced by generation of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics